Diabetes and HIV: the role of a specialist clinic

Samarasinghe, Yohan; McIntosh, C.; Fehér,

doi:10.1002/pdi.783

Cited by 5 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result of that, the incidence of 11 diabetes mellitus is increasing in the HIV infected population more than that of the general population, even in the absence of the concomitant problem of obesity (20 (23). The overall prevalence of glucose disorders in HIV-infected patients treated with HAART, which includes diabetes mellitus, impaired fasting glucose and impaired glucose tolerance, was found to be at 25% for that particular study (23).…”

Section: Diabetes Among Hiv Positive Patientsmentioning

confidence: 91%

The Burden of Metabolic Diseases Amongst HIV Positive Patients on HAART Attending the Johannesburg Hospital

Julius¹,

Basu²,

Ricci³

et al. 2011

CHR

View full text Add to dashboard Cite

Section: Diabetes Among Hiv Positive Patientsmentioning

confidence: 91%

The Burden of Metabolic Diseases Amongst HIV Positive Patients on HAART Attending the Johannesburg Hospital

Julius¹,

Basu²,

Ricci³

et al. 2011

CHR

View full text Add to dashboard Cite

“…This inhibition leads to inflammation and insulin resistance. 13,[16][17][18] NRTIs Treatment with NRTI drugs, in particular, thymidine analogs such as d4T (stavudine), can cause mitochondrial toxicity, which induces fat cell apoptosis or cell death. Elevated free fatty acids and rates of lipolysis lead to lipodystrophic syndrome, and this is associated with insulin resistance, hypertriglyceridemia, low HDL-C, and the metabolic syndrome.…”

Section: Effects Of Haart Pismentioning

confidence: 99%

Management of the Metabolic Syndrome in Patients With Human Immunodeficiency Virus

Feigenbaum

Longstaff

2010

Diabetes Educ

View full text Add to dashboard Cite

Patients with human immunodeficiency virus (HIV) are an increasing subpopulation of patients seen in endocrine/diabetes clinics. This article explores evidence-based treatment recommendations for patients with metabolic syndrome who are also positive for HIV. Patients infected with HIV may manifest metabolic abnormalities. They often present with low high-density lipoprotein (HDL-C), hypertension, visceral adiposity, and insulin resistance, among other symptoms consistent with features of the metabolic syndrome. The etiologies of the metabolic abnormalities are not completely understood. The role of highly active antiretroviral therapy (HAART) and the separate effect of HIV on patients who are surviving longer may contribute to the increased incidence of the development of the metabolic syndrome. The role of the health care team is to provide patient education to patients with HIV concerning lifestyle modification in order to prevent complications related to the metabolic syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

“…T2DM prevalence and complication rates in the HIV-infected population (23–40%) are noticeably higher than the general population [9]. Traditional risk factors as well as HIV-specific factors including anti-retrovirals and lipodystrophy syndrome contribute to the pathogenesis [9]. A strong body of evidence supports the use of bariatric surgery as a treatment modality for T2DM in the context of obesity [10] with sustained remission of T2DM described [7].…”

Section: Discussionmentioning

confidence: 99%

Bariatric surgery in individuals with human immunodeficiency virus and type 2 diabetes: a case series

et al. 2019

View full text Add to dashboard Cite

Background The efficacy and safety of bariatric surgery have not been fully elucidated in patients affected with human immunodeficiency virus. Although adjustable gastric banding and sleeve gastrectomy are starting to be used in patients with human immunodeficiency virus, there are limited descriptions of the outcomes of type 2 diabetes mellitus in individuals who are human immunodeficiency virus positive and undergoing these procedures. Case presentation We have evaluated retrospectively three patients who underwent adjustable gastric banding or sleeve gastrectomy, the effect in weight reduction and glycemic control as well as its impact on human immunodeficiency virus management. Case 1 (adjustable gastric banding), a 58-year-old Caucasian male, achieved 19% total weight loss, Case 2, a 33-year-old Caucasian male (sleeve gastrectomy) lost 25%, and Case 3, a 48-year-old Caucasian female (sleeve gastrectomy), lost 14% postoperation. In terms of type 2 diabetes mellitus, Case 2 achieved complete remission according to American Diabetes Association criteria, while Case 1 would also have achieved remission were it not for the continuation of metformin postoperatively. Insulin requirements and pill burden were markedly reduced in Case 3 after sleeve gastrectomy, although lack of remission was predictable given the longevity of type 2 diabetes mellitus and preoperative insulin dosage. In all three cases, human immunodeficiency virus status did not appear to be affected by the bariatric surgery which was supported by the postoperative stable CD4 count and undetectable viral load. Conclusions Bariatric surgery is a safe and effective treatment modality in patients who are human immunodeficiency virus positive with obesity and type 2 diabetes mellitus.

show abstract

Diabetes and HIV: the role of a specialist clinic

Cited by 5 publications

References 41 publications

The Burden of Metabolic Diseases Amongst HIV Positive Patients on HAART Attending the Johannesburg Hospital

The Burden of Metabolic Diseases Amongst HIV Positive Patients on HAART Attending the Johannesburg Hospital

Management of the Metabolic Syndrome in Patients With Human Immunodeficiency Virus

Bariatric surgery in individuals with human immunodeficiency virus and type 2 diabetes: a case series

Contact Info

Product

Resources

About